Role of pharmacotherapy in Brugada syndrome
Author Information
Author(s): Takeshi Tsuchiya
Primary Institution: Hakuaikai Hospital
Hypothesis
Can pharmacological therapies effectively manage Brugada syndrome and prevent ventricular fibrillation?
Conclusion
Pharmacological therapies, particularly quinidine, may be effective in preventing ventricular fibrillation in patients with Brugada syndrome.
Supporting Evidence
- Quinidine has been shown to effectively prevent ventricular fibrillation in patients with Brugada syndrome.
- Electrophysiologic study-guided therapy with class IA agents was effective in preventing sustained polymorphic ventricular tachycardia in 96% of patients.
- Patients treated with quinidine did not experience sustained ventricular arrhythmia during a mean follow-up of 9.1 years.
Takeaway
Brugada syndrome can cause dangerous heart rhythms, but certain medications might help keep people safe from these problems.
Methodology
The study reviewed various pharmacological therapies and their effects on patients with Brugada syndrome, including case reports and clinical observations.
Potential Biases
Potential bias due to lack of randomized controlled trials and reliance on case reports.
Limitations
There are risks of side effects and loss of efficacy with antiarrhythmic agents, and no randomized controlled trials have been conducted on quinidine therapy.
Participant Demographics
Patients with idiopathic ventricular fibrillation, including those diagnosed with Brugada syndrome.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website